07 Dec 2021 Sequana Medical announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion Member news
23 Nov 2021 Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease Member news
15 Nov 2021 OXURION NV - First patient dosed in Part B of Phase 2 KALAHARI study evaluating multiple administrations of THR-149 versus aflibercept for treatment of Diabetic Macular Edema (DME) Member news
13 Oct 2021 Oxurion NV announces first patient dosed in its Phase 2 Study evaluating THR-687 for the treatment of Diabetic Macular Edema (DME) Member news
06 Oct 2021 Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer Member news
04 Oct 2021 Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease Member news
04 Oct 2021 Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON) Member news
30 Sep 2021 OXURION announces positive results from Part A of Phase 2 Study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
